First Pacific Advisors’s AbbVie ABBV Stock Holding History

First Pacific Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,850	Closed	-$662K	–	124
2017 Q4	$662K	Buy	+6,850	New	+$646K	0.01%	110
2016 Q2	–	Sell	-56,050	Closed	-$3.2M	–	105
2016 Q1	$3.2M	Sell	56,050 -19,450	-26%	-$1.08M	0.03%	85
2015 Q4	$4.47M	Buy	+75,500	New	+$4.35M	0.04%	82

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

First Pacific Advisors's ABBV Position: Q1 2018 in Review

First Pacific Advisors sold out of AbbVie (ABBV) in Q1 2018, closing a stake of 6,850 shares — an estimated $662K sold.

First Pacific Advisors first reported a position in ABBV in Q4 2015 and held it in 3 quarters. The position peaked at $4.47M in Q4 2015. 2,015 funds tracked by Wall St. Rank hold ABBV as of Q1 2018.

First Pacific Advisors reported no remaining AbbVie position as of Q1 2018 after selling out during the quarter.
First Pacific Advisors sold 6,850 AbbVie shares in Q1 2018, an estimated $662K.
First Pacific Advisors first reported a position in AbbVie in Q4 2015 and held it in 3 quarters.
First Pacific Advisors's AbbVie position peaked at $4.47M in Q4 2015.
2,015 funds tracked by Wall St. Rank held AbbVie as of Q1 2018.

Based on First Pacific Advisors's 13F filing for Q1 2018, filed 14 May 2018.